PMID- 33228573 OWN - NLM STAT- MEDLINE DCOM- 20210210 LR - 20210210 IS - 1471-244X (Electronic) IS - 1471-244X (Linking) VI - 20 IP - 1 DP - 2020 Nov 23 TI - Real-world clinical features of and antidepressant prescribing patterns for outpatients with bipolar disorder. PG - 555 LID - 10.1186/s12888-020-02967-5 [doi] LID - 555 AB - BACKGROUND: Several evidence-based practice guidelines have been developed to better treat bipolar disorder. However, the articles cited in these guidelines were not sufficiently based on real-world clinical practice. METHODS: The MUlticenter treatment SUrvey on BIpolar disorder in Japanese psychiatric clinics (MUSUBI) is a study conducted to accumulate evidence on the real-world practical treatment of bipolar disorder. Psychiatrists were asked to complete a questionnaire about patients with bipolar disorder by performing a retrospective medical record survey. The questionnaire included patient characteristics (age, gender, height, weight, academic background, and occupational status), comorbidities, mental status, treatment period, Global Assessment of Functioning (GAF) score, and details of pharmacological treatment. RESULTS: Data on 2705 patients were included in this study. The proportion of patients receiving antidepressant prescriptions was 40.9%. The most commonly used antidepressant was duloxetine, and the most frequently used antidepressant class was selective serotonin reuptake inhibitors (SSRIs). Binomial logistic regression analysis and bivariate analysis revealed that the usage of antidepressants was correlated with low prescription rates for mood stabilizers, high prescription rates for anxiolytics and hypnotics, and low GAF scores. In addition, patients in a depressive state had a significantly higher rate of antidepressant prescriptions than patients with other mental states. CONCLUSIONS: Approximately 40% of patients in Japan with a diagnosis of bipolar disorder have received antidepressants. Antidepressants were most often prescribed in combination with mood stabilizers, antipsychotics or both. Patients who were prescribed antidepressants received fewer mood stabilizers, more anxiolytics, and more hypnotics than those who did not receive antidepressant prescriptions. FAU - Tokumitsu, Keita AU - Tokumitsu K AD - Department of Psychiatry, Dokkyo Medical University, School of Medicine, Mibu, Shimotsuga, Tochigi, 321-0293, Japan. FAU - Yasui-Furukori, Norio AU - Yasui-Furukori N AUID- ORCID: 0000-0002-4414-3770 AD - Department of Psychiatry, Dokkyo Medical University, School of Medicine, Mibu, Shimotsuga, Tochigi, 321-0293, Japan. furukori@dokkyomed.ac.jp. AD - The Japanese Society of Clinical Neuropsychopharmacology, Tokyo, Japan. furukori@dokkyomed.ac.jp. FAU - Adachi, Naoto AU - Adachi N AD - The Japanese Association of Neuro-Psychiatric Clinics, Tokyo, Japan. FAU - Kubota, Yukihisa AU - Kubota Y AD - The Japanese Association of Neuro-Psychiatric Clinics, Tokyo, Japan. FAU - Watanabe, Yoichiro AU - Watanabe Y AD - The Japanese Association of Neuro-Psychiatric Clinics, Tokyo, Japan. FAU - Miki, Kazuhira AU - Miki K AD - The Japanese Association of Neuro-Psychiatric Clinics, Tokyo, Japan. FAU - Azekawa, Takaharu AU - Azekawa T AD - The Japanese Association of Neuro-Psychiatric Clinics, Tokyo, Japan. FAU - Edagawa, Koji AU - Edagawa K AD - The Japanese Association of Neuro-Psychiatric Clinics, Tokyo, Japan. FAU - Katsumoto, Eiichi AU - Katsumoto E AD - The Japanese Association of Neuro-Psychiatric Clinics, Tokyo, Japan. FAU - Hongo, Seiji AU - Hongo S AD - The Japanese Association of Neuro-Psychiatric Clinics, Tokyo, Japan. FAU - Goto, Eiichiro AU - Goto E AD - The Japanese Association of Neuro-Psychiatric Clinics, Tokyo, Japan. FAU - Ueda, Hitoshi AU - Ueda H AD - The Japanese Association of Neuro-Psychiatric Clinics, Tokyo, Japan. FAU - Kato, Masaki AU - Kato M AD - The Japanese Society of Clinical Neuropsychopharmacology, Tokyo, Japan. AD - Department of Neuropsychiatry, Kansai Medical University, Osaka, Japan. FAU - Yoshimura, Reiji AU - Yoshimura R AD - The Japanese Society of Clinical Neuropsychopharmacology, Tokyo, Japan. AD - Department of Psychiatry, University of Occupational and Environmental Health, Fukuoka, Japan. FAU - Nakagawa, Atsuo AU - Nakagawa A AD - The Japanese Society of Clinical Neuropsychopharmacology, Tokyo, Japan. AD - Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan. FAU - Kikuchi, Toshiaki AU - Kikuchi T AD - The Japanese Society of Clinical Neuropsychopharmacology, Tokyo, Japan. AD - Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan. FAU - Tsuboi, Takashi AU - Tsuboi T AD - The Japanese Society of Clinical Neuropsychopharmacology, Tokyo, Japan. AD - Department of Neuropsychiatry, Kyorin University School of Medicine, Tokyo, Japan. FAU - Shimoda, Kazutaka AU - Shimoda K AD - Department of Psychiatry, Dokkyo Medical University, School of Medicine, Mibu, Shimotsuga, Tochigi, 321-0293, Japan. FAU - Watanabe, Koichiro AU - Watanabe K AD - The Japanese Society of Clinical Neuropsychopharmacology, Tokyo, Japan. AD - Department of Neuropsychiatry, Kyorin University School of Medicine, Tokyo, Japan. LA - eng PT - Journal Article PT - Multicenter Study PT - Research Support, Non-U.S. Gov't DEP - 20201123 PL - England TA - BMC Psychiatry JT - BMC psychiatry JID - 100968559 RN - 0 (Antidepressive Agents) SB - IM MH - Antidepressive Agents/therapeutic use MH - *Bipolar Disorder/drug therapy MH - Humans MH - Japan MH - Outpatients MH - Retrospective Studies PMC - PMC7686705 OTO - NOTNLM OT - Antidepressant OT - Bipolar disorder OT - Nationwide study OT - Real world COIS- Yasui-Furukori has received grant/research support or honoraria from and has been a speaker for Dainippon-Sumitomo Pharma, Mochida Pharmaceutical, MSD, and Otsuka Pharmaceutical. Shimoda has received research support from Novartis Pharma, Dainippon Sumitomo Pharma, Astellas Pharma, Meiji Seika Pharma, Eisai, Pfizer, Otsuka Pharmaceutical, Daiichi Sankyo, and Takeda Pharmaceutical and honoraria from Eisai, Mitsubishi Tanabe Pharma, Takeda Pharmaceutical, Meiji Seika Pharma, Janssen Pharmaceutical, Shionogi, Dainippon Sumitomo Pharma, Daiichi Sankyo, and Pfizer. Yoshimura has received speaker honoraria from Eli Lilly, Janssen, Dainippon Sumitomo, Otsuka, Meiji, Pfizer and Shionogi. Kato has received grant funding from the Japan Society for the Promotion of Science, SENSHIN Medical Research Foundation and the Japan Research Foundation for Clinical Pharmacology and has received speaker honoraria from Dainippon-Sumitomo Pharma, Otsuka, Meiji-Seika Pharma, Eli Lilly, MSD K.K., GlaxoSmithKline, Pfizer, Janssen Pharmaceutical, Shionogi, Mitsubishi Tanabe Pharma, Takeda Pharmaceutical and Ono Pharmaceutical. Azegawa has received speaker honoraria from Eli Lilly, Otsuka Pharmaceutical, and Pfizer. Ueda has received manuscript fees or speaker honoraria from Eli Lilly, Janssen Pharmaceutical, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, MSD, Otsuka Pharmaceutical, Pfizer, Sumitomo Dainippon Pharma, Takeda Pharmaceutical, and Yoshitomi Yakuhin. Edagawa has received speaker honoraria from Eli Lilly, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, MSD, Otsuka Pharmaceutical, Pfizer, Sumitomo Dainippon Pharma, Kyowa and Yoshitomi Yakuhin. Katsumoto has received speaker honoraria from Daiichi Sankyo, Eisai, Eli Lilly, Janssen Pharmaceutical, Kyowa Pharmaceutical, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, MSD, Otsuka Pharmaceutical, Pfizer, Sumitomo Dainippon Pharma, and UCB. Kubota has received consultant fees from Pfizer and Meiji-Seika Pharma and speaker honoraria from Meiji-Seika Pharma, Eli Lilly, Janssen Pharmaceutical, Dainippon Sumitomo Pharma, Mitsubishi Tanabe Pharma, Yoshitomi Yakuhin, Otsuka Pharmaceutical, and Eisai. Goto has received manuscript fees or speaker honoraria from Eli Lilly, Janssen Pharmaceutical, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, MSD, Otsuka Pharmaceutical, and Sumitomo Dainippon Pharma. Hongo has received manuscript fees or speaker honoraria from Eli Lilly, Janssen Pharmaceutical, Kyowa Pharmaceutical, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, Otsuka Pharmaceutical, Pfizer, Shionogi, Sumitomo Dainippon Pharma, and Yoshitomi Yakuhin. Tsuboi has received consultant fees from Pfizer and speaker honoraria from Eli Lilly, Meiji-Seika Pharma, MSD, Janssen Pharmaceutical, Dainippon Sumitomo Pharma, Mitsubishi Tanabe Pharma, Yoshitomi Yakuhin, Mochida Pharmaceutical, Otsuka Pharmaceutical, Kyowa Pharmaceutical, and Takeda Pharmaceutical. Nakagawa has received lecture fees from Pfizer, Eli Lilly, Otsuka, Janssen Pharmaceutical, Mitsubishi Tanabe, Mochida, Dainippon Sumitomo and NTT Docomo and has served on advisory boards for Takeda, Meiji Seika and Tsumura. Kikuchi has received consultant fees from Takeda Pharmaceutical and the Center for Cognitive Behavioral Therapy and Training. Watanabe has received manuscript fees or speaker honoraria from Daiichi Sankyo, Eisai, Eli Lilly, GlaxoSmithKline, Janssen Pharmaceutical, Kyowa Pharmaceutical, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, MSD, Otsuka Pharmaceutical, Pfizer, Shionogi, Sumitomo Dainippon Pharma, Takeda Pharmaceutical, and Yoshitomi Yakuhin; has received research/grant support from Astellas Pharma, Daiichi Sankyo, Eisai, MSD, Mitsubishi Tanabe Pharma, Meiji Seika Pharma, Otsuka Pharmaceutical, Pfizer, Shionogi, and Sumitomo Dainippon Pharma; and is a consultant for Eisai, Eli Lilly, Kyowa Pharmaceutical, Otsuka Pharmaceutical, Pfizer, Sumitomo Dainippon Pharma, Taisho Toyama Pharmaceutical, and Takeda Pharmaceutical. EDAT- 2020/11/25 06:00 MHDA- 2021/02/11 06:00 PMCR- 2020/11/23 CRDT- 2020/11/24 05:37 PHST- 2020/06/29 00:00 [received] PHST- 2020/11/17 00:00 [accepted] PHST- 2020/11/24 05:37 [entrez] PHST- 2020/11/25 06:00 [pubmed] PHST- 2021/02/11 06:00 [medline] PHST- 2020/11/23 00:00 [pmc-release] AID - 10.1186/s12888-020-02967-5 [pii] AID - 2967 [pii] AID - 10.1186/s12888-020-02967-5 [doi] PST - epublish SO - BMC Psychiatry. 2020 Nov 23;20(1):555. doi: 10.1186/s12888-020-02967-5.